What is Surrozen, Inc. Warrant's earnings per share (EPS)?

Surrozen, Inc. Warrant (SRZNW) reported diluted earnings per share of -$32.37 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Surrozen, Inc. Warrant (SRZNW) Financials

SRZNW

Trailing 12 months to June 30, 2026

Revenue $11.5M YoY not available

Net Income -$332.1M YoY not available

EPS (Diluted) -$32.37 FY2025 annual

Free Cash Flow -$35.0M -86.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SRZNW SEC filings page.

Surrozen, Inc. Warrant (SRZNW) reported $11.5M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SRZNW FY2025 2026-08-29

Development-stage economics remain dependent on financing: persistent R&D spending and operating cash use coexist with a deeply negative equity base.

In FY2025, R&D spending of $29.4M was 8.4x revenue of $3.5M, while operating cash flow of -$30.2M nearly matched R&D; the cash profile is therefore dominated by development investment rather than sales scale. The earnings-to-cash gap also widened sharply: net loss was -$242.0M against operating loss of -$42.1M, indicating a large below-operating-line effect alongside external financing of $85.1M.

By FY2025, liabilities of $286.5M exceeded assets of $98.7M by a wide margin, so the balance sheet is not supported by its recorded asset base. Negative equity of -$187.8M makes that financing structure especially consequential.

The current ratio rose from 5.3x in FY2024 to 9.2x in FY2025 even as operating cash flow remained negative, suggesting that short-term accounting coverage improved without changing the underlying need to fund operations.

Financial Health Signals

Financial Health Score 41/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Surrozen, Inc. Warrant's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Surrozen, Inc. Warrant held $89.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $30.2M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Surrozen, Inc. Warrant scores 59/100 among other emerging companies.

Dilution

Surrozen, Inc. Warrant had 10M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Surrozen, Inc. Warrant scores 9/100 among other emerging companies.

R&D Intensity

Surrozen, Inc. Warrant spent $29.4M on research and development in fiscal year 2025, which was 64.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Surrozen, Inc. Warrant scores 87/100 among other emerging companies.

Revenue Progress

Surrozen, Inc. Warrant reported revenue of $3.5M in fiscal year 2025, against $10.7M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Surrozen, Inc. Warrant scores 1/100 among other emerging companies.

Burn Trend

Surrozen, Inc. Warrant's operations used $30.2M of cash in fiscal year 2025, against $17.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Surrozen, Inc. Warrant scores 58/100 among other emerging companies.

Balance Sheet

Surrozen, Inc. Warrant's cash, cash equivalents and investments came to $89.2M at the end of fiscal year 2025, against $286.5M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Surrozen, Inc. Warrant scores 34/100 among other emerging companies.

Piotroski F-Score Partial

2/7

Surrozen, Inc. Warrant passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Surrozen, Inc. Warrant reported a net loss of $242.0M while operations used $30.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.0M

YoY+408.6%

QoQ0.0%

Surrozen, Inc. Warrant generated $5.0M in revenue in Q2 2026. This represents an increase of 408.6% from the same quarter a year earlier. It is unchanged from the prior quarter.

Net Income

$50.2M

YoY+26.2%

QoQ+139.4%

Surrozen, Inc. Warrant reported $50.2M in net income in Q2 2026. This represents an increase of 26.2% from the same quarter a year earlier. Against the prior quarter it is up 139.4%.

EPS (Diluted)

-$0.41

YoY-116.1%

QoQ+96.5%

Surrozen, Inc. Warrant earned -$0.41 per diluted share (EPS) in Q2 2026. This represents a decrease of 116.1% from the same quarter a year earlier. Against the prior quarter it is up 96.5%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$7.4M

YoY-21.3%

QoQ+41.1%

Surrozen, Inc. Warrant recorded an outflow of $7.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 21.3% from the same quarter a year earlier. Against the prior quarter it is up 41.1%.

Cash & Debt

$102.0M

YoY+12.9%

QoQ-4.6%

5Y CAGR+40.2%

Surrozen, Inc. Warrant held $102.0M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

12M

YoY+37.1%

QoQ+2.3%

Surrozen, Inc. Warrant had 12M shares outstanding in Q2 2026. This represents an increase of 37.1% from the same quarter a year earlier. Against the prior quarter it is up 2.3%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$8.5M

YoY+40.4%

QoQ-9.0%

Surrozen, Inc. Warrant invested $8.5M in research and development in Q2 2026. This represents an increase of 40.4% from the same quarter a year earlier. Against the prior quarter it is down 9.0%.

Capital Expenditures

$19K

YoY+5.6%

QoQ-84.2%

5Y CAGR-20.8%

Surrozen, Inc. Warrant invested $19K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 5.6% from the same quarter a year earlier. Against the prior quarter it is down 84.2%.

Share Buybacks

Not reported for Q2 2026.

SRZNW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SRZNW quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	$11.5M	$3.5M-67.4%	$10.7M	$0-100.0%	$12.5M	$0	N/A
R&D Expenses	$34.6M	$29.4M+39.0%	$21.1M-22.4%	$27.2M-26.4%	$37.0M-7.9%	$40.2M+56.4%	$25.7M
SG&A Expenses	$21.3M	$16.2M+7.6%	$15.1M-4.7%	$15.8M-20.3%	$19.8M+39.5%	$14.2M+99.6%	$7.1M
Operating Income	-$44.4M	-$42.1M-64.8%	-$25.5M+44.2%	-$45.8M-3.2%	-$44.3M+18.5%	-$54.4M-65.8%	-$32.8M
EBITDA	N/A	-$41.6M-72.4%	-$24.1M+45.1%	-$43.9M-3.5%	-$42.4M+19.0%	-$52.3M-69.5%	-$30.9M
Income Tax	N/A	$0	$0	$0	$0	$0	$0
Net Income	-$332.1M	-$242.0M-280.8%	-$63.6M-47.7%	-$43.0M-19.5%	-$36.0M+34.1%	-$54.6M-67.0%	-$32.7M
EPS (Basic)	N/A	-$32.37-49.4%	-$21.67-1.6%	-$21.33-37.1%	-$15.56-604.1%	-$2.21	N/A
EPS (Diluted)	—	-$32.37	-$21.67-1.6%	-$21.33-37.1%	-$15.56	-$2.21	N/A
Diluted Shares (Avg)	N/A	7,478	2,933+45.3%	2,018-12.8%	2,314	24,689	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$5.0M+408.6%	$5.0M+408.6%	$528K	$983K-90.2%	$983K	$983K	N/A	$10.0M
R&D Expenses	$8.5M+40.4%	$9.3M+42.2%	$9.0M	$7.8M+49.5%	$6.0M+13.3%	$6.6M+25.0%	N/A	$5.2M-14.9%
SG&A Expenses	$6.9M+74.0%	$6.1M+54.1%	$4.2M	$4.1M+14.7%	$4.0M+6.6%	$4.0M+2.4%	N/A	$3.6M-0.1%
Operating Income	-$10.4M-15.0%	-$10.5M-9.5%	-$12.6M	-$10.9M-983.5%	-$9.0M+0.4%	-$9.6M-4.6%	N/A	$1.2M+111.0%
EBITDA	N/A	-$10.4M-12.3%	N/A	N/A	N/A	-$9.3M-5.9%	N/A	N/A
Income Tax	$0	$0	N/A	N/A	$0	$0	N/A	N/A
Net Income	$50.2M+26.2%	-$127.5M-372.8%	-$183.2M	-$71.6M-4896.0%	$39.7M+257.3%	-$27.0M-205.4%	N/A	-$1.4M+86.3%
EPS (Basic)	$2.75+7.8%	-$11.65-56.8%	N/A	-$8.36-1800.0%	$2.55+131.9%	-$7.43-75.2%	N/A	-$0.44+91.4%
EPS (Diluted)	-$0.41-116.1%	-$11.65	N/A	-$8.36	$2.55	-$7.43	N/A	-$0.44
Diluted Shares (Avg)	23M+171.0%	10,949	N/A	8,571	9M	3,628	N/A	3,228

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

SRZNW Balance Sheet

SRZNW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$98.7M+103.7%	$48.5M+5.2%	$46.1M-48.5%	$89.4M-34.8%	$137.2M+121.0%	$62.1M
Current Assets	$91.6M+135.2%	$38.9M-5.3%	$41.1M-49.4%	$81.3M-22.7%	$105.2M+109.4%	$50.2M
Cash & Equivalents	$89.2M+158.2%	$34.6M-4.1%	$36.0M+46.0%	$24.7M-25.4%	$33.1M-5.4%	$35.0M
Short-Term Investments	$0	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0-100.0%	$2.0M-5.3%	$2.2M+8.8%	$2.0M	$0	N/A
Long-Term Investments	$0	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$286.5M+310.2%	$69.8M+757.5%	$8.1M-39.4%	$13.4M-51.1%	$27.5M+86.0%	$14.8M
Current Liabilities	$9.9M+35.7%	$7.3M+2.3%	$7.1M-26.6%	$9.7M-28.3%	$13.6M+86.5%	$7.3M
Non-Current Liabilities	$276.6M+342.3%	$62.5M+6172.0%	$997K-73.1%	$3.7M-73.4%	$13.9M+85.6%	$7.5M
Total Equity	-$187.8M-778.2%	-$21.4M-156.4%	$37.9M-50.1%	$76.0M-30.7%	$109.7M+132.0%	$47.3M
Retained Earnings	-$527.3M-84.8%	-$285.3M-28.7%	-$221.7M-24.1%	-$178.7M-25.2%	-$142.6M-62.1%	-$88.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$115.6M+12.6%	$120.7M+5.1%	$98.7M+103.7%	$94.0M+95.9%	$102.7M+127.9%	$114.8M+212.7%	$48.5M+5.2%	$48.0M-11.1%
Current Assets	$109.4M+16.1%	$113.9M+7.5%	$91.6M+135.2%	$85.9M+89.6%	$94.2M+126.3%	$106.0M+231.1%	$38.9M-5.3%	$45.3M-6.4%
Cash & Equivalents	$102.0M+12.9%	$106.9M+5.2%	$89.2M+158.2%	$81.3M+162.3%	$90.4M+139.3%	$101.6M+272.5%	$34.6M-4.1%	$31.0M-8.7%
Accounts Receivable	$5.0M+115.8%	$5.0M+134.7%	$0-100.0%	$2.3M-81.0%	$2.3M+9.7%	$2.1M+0.1%	$2.0M-5.3%	$12.2M+516.6%
Total Liabilities	$334.3M+501.4%	$398.9M+265.4%	$286.5M+310.2%	$117.6M+177.7%	$55.6M+42.5%	$109.2M+1558.9%	$69.8M+757.5%	$42.3M+401.4%
Current Liabilities	$9.0M+56.9%	$9.6M-9.6%	$9.9M+35.7%	$6.5M+6.7%	$5.7M-4.0%	$10.6M+71.3%	$7.3M+2.3%	$6.1M-8.3%
Non-Current Liabilities	$325.3M+552.6%	$389.3M+294.9%	$276.6M+342.3%	$111.0M+206.6%	$49.8M+50.9%	$98.6M+24481.8%	$62.5M+6172.0%	$36.2M+1945.8%
Total Equity	-$218.7M-564.1%	-$278.1M-5002.1%	-$187.8M-778.2%	-$23.5M-514.9%	$47.1M+677.2%	$5.7M-81.2%	-$21.4M-156.4%	$5.7M-87.6%
Retained Earnings	-$604.6M-121.9%	-$654.8M-109.7%	-$527.3M-84.8%	-$344.1M-33.8%	-$272.5M-6.5%	-$312.2M-35.4%	-$285.3M-28.7%	-$257.2M-20.9%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.

SRZNW Cash Flow Statement

SRZNW quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$34.8M	-$30.2M-71.6%	-$17.6M+56.3%	-$40.4M+8.6%	-$44.1M+9.6%	-$48.8M-67.7%	-$29.1M
Depreciation & Amortization	N/A	$537K-62.8%	$1.4M-24.5%	$1.9M-2.3%	$2.0M-5.4%	$2.1M+6.7%	$1.9M
Stock-Based Compensation	N/A	$3.8M-6.8%	$4.1M-5.9%	$4.4M-3.2%	$4.5M+95.0%	$2.3M+264.7%	$635K
Capital Expenditures	$222K	$128K+392.3%	$26K-93.5%	$398K-45.3%	$728K-42.6%	$1.3M+45.2%	$874K
Free Cash Flow	-$35.0M	-$30.4M-72.0%	-$17.7M+56.7%	-$40.8M+9.2%	-$44.9M+10.4%	-$50.1M-67.1%	-$30.0M
Investing Cash Flow	-$222K	-$128K-392.3%	-$26K-100.1%	$51.7M+35.0%	$38.3M+149.3%	-$77.7M-415.5%	-$15.1M
Financing Cash Flow	$46.6M	$85.1M+425.8%	$16.2M+5760.9%	$276K+110.8%	-$2.6M-102.1%	$124.6M+149.0%	$50.1M
Share Buybacks	N/A	N/A	N/A	$0-100.0%	$2.6M	$0	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$7.4M-21.3%	-$12.5M-34.7%	-$5.8M-267.0%	-$9.0M-33.9%	-$6.1M-8.9%	-$9.3M-6.1%	$3.5M+147.6%	-$6.8M+33.4%
Depreciation & Amortization	N/A	$65K-77.9%	N/A	N/A	N/A	$294K-25.0%	N/A	N/A
Stock-Based Compensation	N/A	$2.1M+152.4%	N/A	N/A	N/A	$834K-19.0%	N/A	N/A
Capital Expenditures	$19K+5.6%	$120K+344.4%	$59K+210.5%	$24K	$18K	$27K+285.7%	$19K	$0
Free Cash Flow	-$7.4M-21.3%	-$12.6M-35.6%	-$5.9M-269.6%	-$9.1M-34.2%	-$6.1M-9.3%	-$9.3M-6.3%	$3.5M+147.4%	-$6.8M+33.4%
Investing Cash Flow	-$19K-5.6%	-$120K-344.4%	-$59K-210.5%	-$24K	-$18K	-$27K-285.7%	-$19K-100.2%	$0-100.0%
Financing Cash Flow	$2.5M+149.0%	$30.3M-60.4%	$13.8M+15044.0%	$9K+1000.0%	-$5.1M-131.9%	$76.4M	$91K-35.5%	-$1K+92.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SRZNW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SRZNW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Margin	-1210.6%	-239.7%	N/A	-354.7%	N/A	N/A
Net Margin	-6960.8%	-596.6%	N/A	-288.0%	N/A	N/A
Return on Equity	N/A	N/A	-113.5%-66.1pp	-47.4%+2.4pp	-49.8%+19.4pp	-69.2%
Return on Assets	-245.1%-114.0pp	-131.2%-37.7pp	-93.4%-53.2pp	-40.3%-0.4pp	-39.8%+12.9pp	-52.7%
Current Ratio	9.22+3.9x	5.32-0.4x	5.75-2.6x	8.35+0.6x	7.75+0.8x	6.90
Debt-to-Equity	N/A	N/A	0.210.0x	0.18-0.1x	0.25-0.1x	0.31
Asset Turnover	0.04-0.2x	0.22+0.2x	0.00-0.1x	0.14+0.1x	0.00	N/A
FCF Margin	-873.5%	-165.7%	N/A	-359.0%	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	-207.4%	-209.1%	-2393.8%	-1107.3%	-917.3%	-971.6%	N/A	12.3%
Net Margin	1003.5%	-2550.1%	-34689.2%	-7288.2%	4043.3%	-2743.6%	N/A	-14.3%
Return on Equity	N/A	N/A	N/A	N/A	84.4%+501.1pp	-475.3%-446.0pp	N/A	-25.3%-2.4pp
Return on Assets	43.4%+4.7pp	-105.6%-82.1pp	-185.5%	-76.2%-73.2pp	38.7%+94.8pp	-23.5%+0.6pp	N/A	-3.0%+16.4pp
Current Ratio	12.14-4.3x	11.91+1.9x	9.22+3.9x	13.15+5.8x	16.41+9.4x	10.02+4.8x	5.32-0.4x	7.40+0.2x
Debt-to-Equity	N/A	N/A	N/A	N/A	1.18-5.3x	19.24+19.0x	N/A	7.47+7.3x
Asset Turnover	0.040.0x	0.040.0x	0.01	0.01-0.2x	0.010.0x	0.010.0x	N/A	0.21+0.2x
FCF Margin	-148.7%	-252.3%	-1111.9%	-922.1%	-623.7%	-946.7%	N/A	-67.5%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$187.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Surrozen, Inc. Warrant SRZNW	FY2025	$3.5M	-$242.0M	N/A	N/A	41/100
Aspire-Lakewood Holdings, Inc. Warrant ASBPW	FY2025	$6K	N/A	N/A	N/A	—
BriaCell Therapeutics Corp. Warrant BCTXW	FY2025	N/A	-$26.3M	N/A	N/A	—
BriaCell Therapeutics Corp. Warrant BCTXZ	FY2025	N/A	-$26.3M	N/A	N/A	—

Where Surrozen, Inc. Warrant Ranks

Frequently Asked Questions

What is Surrozen, Inc. Warrant's annual revenue?

Surrozen, Inc. Warrant (SRZNW) reported $3.5M in total revenue for fiscal year 2025. This represents a -67.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Surrozen, Inc. Warrant's revenue growing?

Surrozen, Inc. Warrant (SRZNW) revenue declined by 67.4% year-over-year, from $10.7M to $3.5M in fiscal year 2025.

Is Surrozen, Inc. Warrant profitable?

No, Surrozen, Inc. Warrant (SRZNW) reported a net income of -$242.0M in fiscal year 2025.

What is Surrozen, Inc. Warrant's EBITDA?

Surrozen, Inc. Warrant (SRZNW) had EBITDA of -$41.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Surrozen, Inc. Warrant's free cash flow?

Surrozen, Inc. Warrant (SRZNW) recorded an outflow of $30.4M in free cash flow during fiscal year 2025. This represents a -72.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Surrozen, Inc. Warrant's operating cash flow?

Surrozen, Inc. Warrant (SRZNW) recorded an outflow of $30.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Surrozen, Inc. Warrant's total assets?

Surrozen, Inc. Warrant (SRZNW) had $98.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Surrozen, Inc. Warrant's capital expenditures?

Surrozen, Inc. Warrant (SRZNW) invested $128K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Surrozen, Inc. Warrant spend on research and development?

Surrozen, Inc. Warrant (SRZNW) invested $29.4M in research and development during fiscal year 2025.

How many shares does Surrozen, Inc. Warrant have outstanding?

Surrozen, Inc. Warrant (SRZNW) had 10M shares outstanding as of fiscal year 2025.

What is Surrozen, Inc. Warrant's current ratio?

Surrozen, Inc. Warrant (SRZNW) had a current ratio of 9.22 as of fiscal year 2025, which is generally considered healthy.

What is Surrozen, Inc. Warrant's return on assets (ROA)?

Surrozen, Inc. Warrant (SRZNW) had a return on assets of -245.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Surrozen, Inc. Warrant's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Surrozen, Inc. Warrant (SRZNW) held $89.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $30.2M over that year. Dividing the one by the other, the reported balance equals about 35 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Surrozen, Inc. Warrant's debt-to-equity ratio negative or not reported?

Surrozen, Inc. Warrant (SRZNW) has negative shareholder equity of -$187.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Surrozen, Inc. Warrant's Piotroski F-Score?

Surrozen, Inc. Warrant (SRZNW) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Surrozen, Inc. Warrant's earnings high quality?

Surrozen, Inc. Warrant (SRZNW) reported a net loss of $242.0M while operations used $30.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Surrozen, Inc. Warrant?

Surrozen, Inc. Warrant (SRZNW) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.